HOROWITZ BENJAMIN A

10% Owner | Director

Identity: SEC reporting-owner CIK · Reporting-owner CIK: 0001166586

Purchase history

Companies traded: 3
Purchases · 12M: 6
Purchases · 24M: 6
Average purchase: $11.3M
Median purchase: $12.6M
Gross purchase value: $67.7M

Companies: Braveheart Bio, Inc. | Navan, Inc. | Scribe Therapeutics, Inc.

6 SEC accession(s) · 2 joint-owner event(s). Values are reported Form 4 transaction values in USD.

Qualifying purchase disclosures

Published	Company	Ticker	Role	Reported value	SEC source
2026-08-11	Braveheart Bio, Inc.	BRVE	10% Owner	$19.8M	Open filing
2026-07-29	Scribe Therapeutics, Inc.	SCTX	10% Owner	$5.0M	Open filing
2026-01-09	Navan, Inc.	NAVN	Director \| 10% Owner	$839.2K	Open filing
2026-01-06	Navan, Inc.	NAVN	Director \| 10% Owner	$15.9M	Open filing
2025-12-29	Navan, Inc.	NAVN	Director \| 10% Owner	$16.7M	Open filing
2025-12-19	Navan, Inc.	NAVN	Director \| 10% Owner	$9.4M	Open filing

Post-purchase outcomes

Excess return = stock return − S&P 500 ETF (SPY adjusted close) return. Returns start on the first shared trading session on or after publication.

Period	Completed events	Price coverage	Hit rate	Median excess return	Average excess return	Worst excess return
5D	2Small Sample	33.3% (2/6)	100.0% (2/2)	+15.7%	+15.7%	+7.4%
20D	2Small Sample	33.3% (2/6)	100.0% (2/2)	+42.1%	+42.1%	+16.7%
60D	0No Data	0.0% (0/4)	—	—	—	—
120D	0No Data	0.0% (0/4)	—	—	—	—

Research patterns

First purchase in 12M: 3/6
Large purchase ≥ $100k: 6/6
Cluster buying · 15D: 6/6
Buying the dip: 0/—

Routine / opportunistic: Not classifiable. These labels never affect the score or ranking.

Small samples remain visible but are not scored. This research enrichment never affects US-v1.1.